Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite (folate antagonist) presented as a subcutaneous injection for subcutaneous use. It is employed to treat autoimmune disorders and certain cancers in adult patients. GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate acts on rapidly dividing cells and modulates immune pathways, making it useful for several disease groups. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: diminishes skin lesions and plaque formation. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Other malignancies: used as part of combination regimens for various solid tumours.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or general weakness. - Oral mucosal ulceration (mouth sores). - Elevated liver enzymes. - Mild decrease in white blood cell count.

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis. - Pulmonary toxicity, including interstitial pneumonitis. - Significant bone marrow suppression leading to anemia or neutropenia. - Life‑threatening infections due to immunosuppression. - Anaphylactic or severe allergic reactions.

Methotrexate requires careful monitoring and specific safety measures. - Liver function monitoring: perform baseline and periodic liver enzyme tests. - Hematologic monitoring: check complete blood counts regularly. - Pregnancy avoidance: contraindicated in pregnancy (Category X) and requires effective contraception. - Breastfeeding restriction: not recommended while nursing. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate can interact with several drug classes, influencing efficacy or toxicity.

Major Interactions (Avoid): - Other folate antagonists (e.g., pemetrexed) – may increase toxicity. - High‑dose non‑steroidal anti‑inflammatory drugs – raise risk of renal impairment. - Live vaccines – heightened risk of infection.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics – may enhance myelosuppression. - Proton pump inhibitors – can alter renal clearance. - Alcohol consumption – increases hepatic toxicity risk. - Trimethoprim‑sulfamethoxazole – may potentiate bone‑marrow suppression.